Replies to post #376878 on Anavex Life Sciences Corp (AVXL)

[12x]

I appreciate you thinking critically, but do you have a different p = 0.029 value than reported by the company in June 2021 to show the PDD ph2 primary endpoint was not met?

From June 2021 Company PR:
-CDR system Continuity of Attention (CoA) (p = 0.029)

From clinicaltrials.gov
Primary Outcome Measures :
Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention [ Time Frame: 14 weeks ]
Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test